In 3 randomised controlled trials (RCTs) in 2496 adults with type 2 diabetes, Toujeo had similar efficacy to insulin glargine 100 units/ml (Lantus) in terms of HbA1c reduction. There was a statistically significant reduction in confirmed or severe nocturnal hypoglycaemia with Toujeo in 2 of the RCTs, but not in the third trial. Severe hypoglycaemic events were rare and not statistically significantly different between Toujeo and Lantus (NICE)
Diabetes News
Tag: Toujeo
Sanofi’s insulin Toujeo® now available for the treatment of adults with diabetes in the UK
New once-daily basal insulin demonstrated similar glycaemic control with a lower incidence of confirmed hypoglycaemia when compared to Lantus® in the treatment of adults with type 2 diabetes
Sanofi announces positive results for Toujeo® in phase iii study extension in Japanese people with uncontrolled diabetes
Toujeo maintained similar blood sugar control vs. Lantus with fewer night-time low blood sugar events over 12-month study period (Sanofi)
Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults
The European Commission has granted marketing authorization in Europe for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults (Sanofi)
Glycosmedia is also available as an App: